| 今开：0.8734 | 昨收：0.871603 |
| 最高：0.89 | 最低：0.813 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：6.7948385E7 |
BioLineRx(BLRX)05-06 19:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001582 Act: 34 Size: 607 KB 网页链接查看全文
BioLineRx(BLRX)05-28 19:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001842 Act: 34 Size: 1 MB 网页链接查看全文
BioLineRx(BLRX)05-24 19:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001827 Act: 34 Size: 599 KB 网页链接查看全文
BioLineRx(BLRX)05-18 05:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001769 Act: 34 Size: 588 KB 网页链接查看全文
BioLineRx(BLRX)05-30 19:25
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001889 Act: 34 Size: 595 KB 网页链接查看全文
greenlandbiotech2018-09-30 21:46
2018年第四个季度要开始了，而第四季度的第一个月，可以说重头戏基本都在一个会议上——10月19日到23日在慕尼黑举办的ESMO（欧洲肿瘤学学会），有多达14个美国上市公司将会在会议上公布最新的临床试验数据。另一方面，这个月有许多小市值公司将迎来非常关键的时刻-PDUFA。因此，本月我们重点推荐关...查看全文
usbiostock2018-05-23 08:52
$BioLineRx Ltd. - American Depositary Shares(BLRX)$ BL-8040联合KEYTEUDA治疗胰腺癌临床2a期试验已完成入组，一线数据预计在2018年下半年公布。查看全文
优游博衍2014-01-23 22:56
$BIOLINERX LTD(BLRX)$ 今天大盘跌所以这只股票虽然有重大利好但是没有大涨，实际上这家公司的基本面还好：市值69百万，股东权益就有50百万；市帐比率4.8还不算高；流动比率、速动比率都在4以上说明财务状况良好；而且更重要的是ODD审核通过了，这是个不错的利基。查看全文
优游博衍2014-01-23 22:45
$BIOLINERX LTD(BLRX)$ 7:11 am BioLineRx receives Orphan Drug Designation for novel stem cell mobilization treatment; BL-8040 expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results expected in H2 2014
ODD通过了是个利好啊查看全文
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001889 Act: 34 Size: 595 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001842 Act: 34 Size: 1 MB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001827 Act: 34 Size: 599 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001769 Act: 34 Size: 588 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001582 Act: 34 Size: 607 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001347 Act: 34 Size: 612 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001285 Act: 34 Size: 595 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001174 Act: 34 Size: 1 MB 网页链接
$BioLineRx(BLRX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-24-001173 Act: 33 Size: 733 KB 网页链接
$BioLineRx(BLRX)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001095 Act: 34 Size: 14 MB 网页链接